MedTrace Logo

Attention Bias Modification for the Improvement of Anxiety in Adolescent and Young Adult Cancer Survivors

NCT06682039 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-01-30

No results posted yet for this study

Summary

This clinical trial studies how well attention bias modification (ABM) improves anxiety in adolescent and young adult (AYA) cancer survivors. Cancer-related anxiety is the most prevalent mental health problem affecting AYA cancer survivors. Cancer-related anxiety is associated with long-term negative outcomes such as poor quality of life, depression, distress, substance use, sleep problems, fatigue, and pain. ABM uses techniques to help patients change the way they react to environmental triggers that may cause a negative reaction. ABM uses brief self-guided smartphone applications. Patients complete repetitive association reaction-time tasks targeting automatic and unconscious negative attention biases to retrain attention away from perceived threat and towards a neutral or positive stimuli. Gratitude-finding and savoring activities are also provided to maintain and increase positive emotions. Using ABM plus gratitude-finding and savoring activities may improve anxiety in AYA cancer survivors.

Conditions

  • Childhood Hematopoietic and Lymphatic System Neoplasm
  • Childhood Malignant Solid Neoplasm

Interventions

OTHER

Internet-Based Intervention

Engage in inert attention task sessions

OTHER

Interview

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Text Message-Based Navigation Intervention

Participants will respond to daily messaging prompts.

OTHER

Internet-Based Intervention

Engage in ABM + text messaging prompts

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Nancy Lau, PhD · Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
29 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-08
Primary Completion
2026-01-12
Completion
2026-01-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06682039 on ClinicalTrials.gov